RPR has had a lot of problems this last year, the biggest one being the closing of their plant in Puerto Rico which was going to make their new antibiotic, Synercid (an awesome product that is beating the resistant 'bugs'). This plant will be closed for a quite a while and their speciality sales force specifically hired to sell this product to the hospitals had to be retrained in other products until this issue is resolved. Needless to say, the stock price took a huge hit because of this. But take heart, their primary care sales force has launched a new, innovative product that seems to be getting good acceptance-- the CombiPatch. It is the first Estrogen and Progesterone patch on the market. Previously, doctors who wanted to prescribe an estrogen patch also had to prescribe a pill for progesterone if they wanted to cycle the hormones, but no more! This one patch is a one stop thing! And RPR seems to have a good 6 months to a year on the competition. Keep a look out for earily results on this product.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat